Total
0
Shares
Small Pharma - CEO, Peter Rands (third from left) and the Small Pharma team.
CEO, Peter Rands (third from left) and the Small Pharma team.
Source: Small Pharma.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Negev Capital, a psychedelic medical intervention fund, has doubled its investment in Small Pharma (DMT)
  • The latest investment increases the cumulative investment to US$1 million
  • Negev believes the company’s expertise, cash on hand and progress with clinical trials makes it a singular investment opportunity
  • Small Pharma is a neuropharmaceutical company specialized in IP-led development of treatments for mental health conditions
  • Small Pharma (DMT) is unchanged trading at $0.36 per share

Negev Capital, a psychedelic medical intervention fund, has doubled its investment in Small Pharma (DMT).

The latest investment increases the cumulative investment to US$1 million.

Negev invests in companies developing novel drugs for psychiatric disorders based on psychedelic compounds. Since its inception in February 2021, the fund has recorded exceptional performance through fifteen investments across the U.S., Canada and Europe valued at over US$20 million.

In February 2021, Small Pharma initiated a clinical program into DMT-assisted therapy. This program includes a Phase I/IIa trial on its lead candidate alongside the development of a robust pipeline of proprietary preclinical assets.

Peter Rands, Small Pharma’s CEO, stated,

“Negev Capital’s ongoing investment in our company is a vote of confidence in our robust pipeline of proprietary assets. Small Pharma’s performance to date is a reflection of our team’s capabilities and potential.”

Ken Belotsky, Partner at Negev Capital, added,

“Small Pharma’s recent market cap of circa US$100 million, including approximately US$42 million in cash, is an exceptional investment opportunity giving consideration to the strong science team and progress in clinical trials. We are excited to play a crucial role in helping such companies to achieve their goals.”

Small Pharma is a neuropharmaceutical company specialized in IP-led development of treatments for mental health conditions.

Small Pharma (DMT) is unchanged trading at $0.36 per share as of 2:22 pm ET.

More From The Market Herald
Theratechnologies - Chief Medical Officer and Senior Vice President Dr. Christian Marsolais

" Theratechnologies (TSX:TH) confirms effectiveness of PDCs against vasculogenic mimicry

Theratechnologies (TH) reports its investigational peptide-drug conjugates (PDCs) are effective in inhibiting vasculogenic mimicry (VM) in ovarian and breast cancer models.

" Euro Asia Pay (CSE:EAP) signs LOI to acquire NexPay

Euro Asia Pay Holdings (EAP) has signed a binding letter of intent to acquire NexPay Pty Ltd., an Australian fintech company.

" Algernon Pharmaceuticals (CSE:AGN) receives $2M payment and applies for Nasdaq listing

Algernon Pharmaceuticals (AGN) has recently received a $2M cash payment from a refundable tax credit program for its clinical research work in Australia.
Peak Fintech Group - CEO, Johnson Joseph.

" Peak Fintech (CSE:PKK) upgrades revenue and earnings guidance

Peak Fintech (PKK) has upgraded its revenue and earnings guidance to account for its planned North American expansion.